President Mung Chiang joins industry leaders during SXSW to discuss the university’s role in shaping the future of pharma ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

J&J said it is seeking a preliminary injunction for Samsung Bioepis' Stelara biosimilar over an unauthorized sublicense deal ...

Hyderabad is rapidly establishing itself as a major life sciences hub, rivaling Bengaluru, thanks to a robust state-supported ...

Eli Lilly also responded to the President's tariff warnings by investing $27 billion to construct four manufacturing ...

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.

Positive results from the Tezspire phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps: Cambridge, UK Tuesday, March 4, 2025, ...

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Across six asthma biologics, adherence differed by the therapy given and was often low or irregular based on three adherence measures, according to a presentation here.This cross-sectional cohort ...

"Amgen and AstraZeneca report results from Phase III trial of Tezspire for CRSwNP" was originally created and published by ...